Bridge Medicines, a biotechnology company established in collaboration with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd., and healthcare investment firms Bay City Capital and Deerfield Management, endeavors to transfer innovative research to patients by employing state-of-the-art drug discovery methods to support academic medicine.Bridge Medicines expands on the initiatives of the independent non-profit organization Tri-Institutional Therapeutics Discovery Institute, also known as Tri-I TDI. Researchers at the Tri-I TDI, founded in 2013, focus on various therapeutic areas.